20051
ORBO™ 609 Amberlite™ XAD®-2 (20/50) 400/200 mg
W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
Synonym(s):
ORBO™ Amberlite™ XAD-2 Tube
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
UNSPSC Code:
47131900
NACRES:
NB.21
material
W,W,W separators
Quality Level
Agency
NIOSH 2534,2537
product line
Amberlite™
ORBO™
composition
Bed A, 400 mg
Bed B, 200 mg
packaging
pkg of 50 ea
manufacturer/tradename
ORBO™ 609
technique(s)
active air sampling: suitable
O.D. × L
8 mm × 110 mm
matrix
XAD-2
particle size
20-50 mesh
application(s)
air monitoring
environmental
industrial hygiene
Looking for similar products? Visit Product Comparison Guide
General description
ORBO™ 609 Amberlite™ XAD®-2 (20/50), 400/200 mg sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.
Legal Information
Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service